IR
IRD.US Opus Genetics, Inc.
- Market cap
- USD 385M
- P/E
- -
- P/B
- 10.02x
- ROE
- -416.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IRD.US undervalued?
Graham numberThe Graham number of Opus Genetics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Opus Genetics, Inc. fundamental analysis
No fundamental analysis for Opus Genetics, Inc. yet.
Opus Genetics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-…
Full company profileOpus Genetics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Opus Genetics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 589K | 39.9M | 19.0M | 11.0M | 14.2M | 5.40M |
| Gross Profit | - | -8.00K | 589K | 39.9M | 19.0M | 11.0M | 14.2M | 5.38M |
| Operating Income | -4.19M | -20.0M | -22.7M | 18.2M | -10.6M | -62.1M | -38.6M | -66.8M |
| EBITDA | -4.76M | -17.8M | -56.7M | 18.2M | -9.97M | -57.5M | -48.1M | -159M |
| Net Income | -6.17M | -24.6M | -56.7M | 17.9M | -9.99M | -57.5M | -49.6M | -160M |
| EPS | -0.87 | -5.28 | -3.82 | 0.87 | -0.46 | -2.15 | -0.80 | -1.57 |
| Balance Sheet | ||||||||
| Total Assets | 1.78M | 17.7M | 26.1M | 49.0M | 53.9M | 36.9M | 50.2M | 95.3M |
| Total Liabilities | 9.34M | 31.1M | 3.86M | 2.75M | 4.04M | 30.1M | 34.9M | 56.9M |
| Shareholders' Equity | -7.56M | -13.5M | 22.2M | 46.2M | 49.9M | 6.72M | 15.3M | 38.4M |
| Cash & Short-term Investments | 1.54M | 16.4M | 24.8M | 42.7M | 50.5M | 30.3M | 45.1M | 89.0M |
| Total Debt | 5.67M | - | 538K | - | - | 18.8M | - | 34.5M |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.59M | -6.80M | -19.4M | 14.3M | -1.11M | -25.6M | -35.3M | -51.6M |
| Capital Expenditure | 25.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 252K |
| Free Cash Flow | -3.62M | -6.80M | -19.4M | 14.3M | -1.11M | -25.6M | -35.3M | -51.9M |
| Ratios | ||||||||
| ROE | - | - | -255.1% | 38.7% | -20.0% | -855.6% | -323.1% | -416.8% |
| ROA | -345.8% | -139.2% | -217.4% | 36.5% | -18.5% | -156.1% | -98.7% | -168.1% |
| Net Profit Margin | - | - | -9,625.3% | 44.9% | -52.4% | -523.4% | -349.3% | -2,966.9% |
| Debt to Equity | - | - | 0.02x | - | - | 2.80x | - | 0.90x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Opus Genetics, Inc. dividends
Opus Genetics, Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 1:4 on Nov 6, 2020.
Who owns Opus Genetics, Inc.
- Insiders 11.17%
- Institutions 68.46%
- Public & others 20.38%
- Shares outstanding 96.7M
- Free float 84.6M
Top funds holding IRD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.33M | 3.33% | +3.98% | Sep 2026 |
| iShares Russell 2000 ETF | 1.74M | 2.49% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 646K | 0.92% | -0.38% | Oct 2026 |
| Fidelity Small Cap Index | 584K | 0.84% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 ETF | 405K | 0.58% | +31.26% | Sep 2026 |
| Fidelity Extended Market Index | 358K | 0.51% | +34.17% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 247K | 0.35% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 211K | 0.30% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 169K | 0.24% | +30.03% | Sep 2026 |
| Fidelity Total Market Index | 161K | 0.23% | +61.08% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 128K | 0.18% | +27.94% | Sep 2026 |
| Fidelity Series Total Market Index | 128K | 0.18% | +48.62% | Sep 2026 |
| Simplify Propel Opportunities ETF | 125K | 0.18% | 0.00% | Oct 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 92.7K | 0.13% | 0.00% | Oct 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 92.7K | 0.13% | +53.41% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 88.2K | 0.13% | +23.66% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 87.9K | 0.13% | +0.27% | Oct 2026 |
| Bridge Builder Small Cap Fund | 87.6K | 0.13% | 0.00% | Oct 2026 |
Top institutions holding IRD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6.12M | 8.76% | +264.16% | Jun 2026 |
| Caligan Partners LP | 6.08M | 8.69% | +0.03% | Jun 2026 |
| Adage Capital Partners Gp LLC | 6.03M | 8.63% | 0.00% | Jun 2026 |
| BIOS CAPITAL MANAGEMENT, LP | 3.68M | 5.27% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.12M | 4.46% | +2,009.44% | Jun 2026 |
| Balyasny Asset Management LLC | 3.09M | 4.42% | +13.61% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.96M | 4.23% | +20.76% | Jun 2026 |
| Boxer Capital Management, LLC | 2.82M | 4.03% | +25.11% | Jun 2026 |
| Trails Edge Capital Partners, LP | 2.74M | 3.93% | +448.73% | Jun 2026 |
| Millennium Management LLC | 2.30M | 3.29% | -12.48% | Jun 2026 |
| Great Point Partners LLC | 1.97M | 2.82% | +507.45% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.95M | 2.78% | -15.90% | Jun 2026 |
| ADAR1 Capital Management LLC | 1.78M | 2.55% | -3.53% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.53M | 2.19% | +367.32% | Jun 2026 |
| Woodline Partners LP | 1.43M | 2.05% | +5.96% | Jun 2026 |
| Geode Capital Management, LLC | 1.37M | 1.96% | +154.06% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.19M | 1.70% | +0.03% | Jun 2026 |
| Opaleye Management Inc | 1.13M | 1.61% | +0.45% | Jun 2026 |
| SummitTX Capital, L.P | 1.01M | 1.44% | 0.00% | Jun 2026 |
| State Street Corp | 790K | 1.13% | +295.16% | Jun 2026 |
Opus Genetics, Inc. company profile
- Company name
- Opus Genetics, Inc.
- Ticker
- IRD.US
- Exchange
- USA Stocks
- Listed since
- May 23, 2005
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 27
- Fiscal year end
- December
- Address
- 8 Davis Drive, Durham, NC, United States, 27713
- Phone
- 984 884 6030
- Website
- opusgtx.com
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
Opus Genetics, Inc. management
10- Dr. George Magrath M.B.A., M.D., M.S.CEO & Director · born 1985
- Dr. Benjamin R. Yerxa Ph.D.President & Director · born 1966
- Mr. Joseph K. Schachle MBAChief Operating Officer · born 1965
- Mr. Robert E. Gagnon CPA, M.B.A.CFO & Principal Accounting Officer · born 1974
- Mr. Chris ErnstChief Technology Officer
- Dr. Andrew Murphy Ph.D.Chief Scientific Officer
- Ms. Jenny KobinInvestor Relations Officer
- Mr. Bernhard Hoffmann M.B.A.Senior Vice President of Corporate Development & Secretary · born 1956
- Ms. Amy Zaremba Rabourn C.P.A., MAccHead of Financial Quality Assurance · born 1981
- Ms. Bindu ManneHead of Market Development & Commercialization